Is  ||| S:0 E:3 ||| VBZ
Breast  ||| S:3 E:10 ||| NNP
Conserving  ||| S:10 E:21 ||| NNP
Therapy  ||| S:21 E:29 ||| NNP
a  ||| S:29 E:31 ||| DT
Safe  ||| S:31 E:36 ||| NNP
Modality  ||| S:36 E:45 ||| NNP
for  ||| S:45 E:49 ||| IN
Early-Stage  ||| S:49 E:61 ||| NNP
Male  ||| S:61 E:66 ||| NNP
Breast  ||| S:66 E:73 ||| NNP
Cancer ||| S:73 E:79 ||| NNP
?  ||| S:79 E:81 ||| .
Male  ||| S:81 E:86 ||| JJ
breast  ||| S:86 E:93 ||| NN
cancer  ||| S:93 E:100 ||| NN
( ||| S:100 E:101 ||| -LRB-
MBC ||| S:101 E:104 ||| NNP
)  ||| S:104 E:106 ||| -RRB-
is  ||| S:106 E:109 ||| VBZ
a  ||| S:109 E:111 ||| DT
rare  ||| S:111 E:116 ||| JJ
disease  ||| S:116 E:124 ||| NN
and  ||| S:124 E:128 ||| CC
lacks  ||| S:128 E:134 ||| VBZ
data-based  ||| S:134 E:145 ||| JJ
treatment  ||| S:145 E:155 ||| NN
guidelines ||| S:155 E:165 ||| NNS
.  ||| S:165 E:167 ||| .
Most  ||| S:167 E:172 ||| JJS
men  ||| S:172 E:176 ||| NNS
are  ||| S:176 E:180 ||| VBP
currently  ||| S:180 E:190 ||| RB
treated  ||| S:190 E:198 ||| VBN
with  ||| S:198 E:203 ||| IN
modified  ||| S:203 E:212 ||| JJ
radical  ||| S:212 E:220 ||| JJ
mastectomy  ||| S:220 E:231 ||| NNS
( ||| S:231 E:232 ||| -LRB-
MRM ||| S:232 E:235 ||| NNP
)  ||| S:235 E:237 ||| -RRB-
or  ||| S:237 E:240 ||| CC
simple  ||| S:240 E:247 ||| JJ
mastectomy  ||| S:247 E:258 ||| NNS
( ||| S:258 E:259 ||| -LRB-
SM ||| S:259 E:261 ||| NNP
) ||| S:261 E:262 ||| -RRB-
.  ||| S:262 E:264 ||| .
We  ||| S:264 E:267 ||| PRP
compared  ||| S:267 E:276 ||| VBD
the  ||| S:276 E:280 ||| DT
oncologic  ||| S:280 E:290 ||| JJ
treatment  ||| S:290 E:300 ||| NN
outcomes  ||| S:300 E:309 ||| NNS
of  ||| S:309 E:312 ||| IN
early-stage  ||| S:312 E:324 ||| NNP
MBC  ||| S:324 E:328 ||| NNP
to  ||| S:328 E:331 ||| TO
determine  ||| S:331 E:341 ||| VB
whether  ||| S:341 E:349 ||| IN
breast  ||| S:349 E:356 ||| JJ
conservation  ||| S:356 E:369 ||| NN
therapy  ||| S:369 E:377 ||| NN
( ||| S:377 E:378 ||| -LRB-
BCT ||| S:378 E:381 ||| NNP
)  ||| S:381 E:383 ||| -RRB-
is  ||| S:383 E:386 ||| VBZ
appropriate ||| S:386 E:397 ||| JJ
.  ||| S:397 E:399 ||| .
We  ||| S:399 E:402 ||| PRP
searched  ||| S:402 E:411 ||| VBD
the  ||| S:411 E:415 ||| DT
Surveillance ||| S:415 E:427 ||| NNP
,  ||| S:427 E:429 ||| ,
Epidemiology ||| S:429 E:441 ||| NNP
,  ||| S:441 E:443 ||| ,
and  ||| S:443 E:447 ||| CC
End  ||| S:447 E:451 ||| NN
Results  ||| S:451 E:459 ||| NNS
database  ||| S:459 E:468 ||| NN
for  ||| S:468 E:472 ||| IN
MBC  ||| S:472 E:476 ||| NNP
cases ||| S:476 E:481 ||| NNS
.  ||| S:481 E:483 ||| .
That  ||| S:483 E:488 ||| DT
cohort  ||| S:488 E:495 ||| NN
was  ||| S:495 E:499 ||| VBD
narrowed  ||| S:499 E:508 ||| VBN
to  ||| S:508 E:511 ||| TO
cases  ||| S:511 E:517 ||| NNS
of  ||| S:517 E:520 ||| IN
stage  ||| S:520 E:526 ||| NN
I-II ||| S:526 E:530 ||| NN
,  ||| S:530 E:532 ||| ,
T1-T2N0  ||| S:532 E:540 ||| NNP
MBC  ||| S:540 E:544 ||| NNP
with  ||| S:544 E:549 ||| IN
surgical  ||| S:549 E:558 ||| JJ
and  ||| S:558 E:562 ||| CC
radiation  ||| S:562 E:572 ||| NN
therapy  ||| S:572 E:580 ||| NN
( ||| S:580 E:581 ||| -LRB-
RT ||| S:581 E:583 ||| NNP
)  ||| S:583 E:585 ||| -RRB-
data  ||| S:585 E:590 ||| NNS
available ||| S:590 E:599 ||| JJ
.  ||| S:599 E:601 ||| .
The  ||| S:601 E:605 ||| DT
patients  ||| S:605 E:614 ||| NNS
had  ||| S:614 E:618 ||| VBD
undergone  ||| S:618 E:628 ||| VBN
MRM ||| S:628 E:631 ||| NNP
,  ||| S:631 E:633 ||| ,
SM ||| S:633 E:635 ||| NNP
,  ||| S:635 E:637 ||| ,
or  ||| S:637 E:640 ||| CC
breast  ||| S:640 E:647 ||| JJ
conservation  ||| S:647 E:660 ||| NN
surgery  ||| S:660 E:668 ||| NN
( ||| S:668 E:669 ||| -LRB-
BCS ||| S:669 E:672 ||| NNP
)  ||| S:672 E:674 ||| -RRB-
with  ||| S:674 E:679 ||| IN
or  ||| S:679 E:682 ||| CC
without  ||| S:682 E:690 ||| IN
postoperative  ||| S:690 E:704 ||| JJ
RT ||| S:704 E:706 ||| NNP
.  ||| S:706 E:708 ||| .
We  ||| S:708 E:711 ||| PRP
calculated  ||| S:711 E:722 ||| VBD
the  ||| S:722 E:726 ||| DT
actuarial  ||| S:726 E:736 ||| JJ
5-year  ||| S:736 E:743 ||| CD
cause-specific  ||| S:743 E:758 ||| JJ
survival  ||| S:758 E:767 ||| NN
( ||| S:767 E:768 ||| -LRB-
CSS ||| S:768 E:771 ||| NNP
) ||| S:771 E:772 ||| -RRB-
.  ||| S:772 E:774 ||| .
We  ||| S:774 E:777 ||| PRP
identified  ||| S:777 E:788 ||| VBD
6263  ||| S:788 E:793 ||| CD
MBC  ||| S:793 E:797 ||| NN
cases  ||| S:797 E:803 ||| NNS
and  ||| S:803 E:807 ||| CC
included  ||| S:807 E:816 ||| VBD
1777  ||| S:816 E:821 ||| CD
men  ||| S:821 E:825 ||| NNS
with  ||| S:825 E:830 ||| IN
stage  ||| S:830 E:836 ||| NN
I  ||| S:836 E:838 ||| PRP
or  ||| S:838 E:841 ||| CC
II ||| S:841 E:843 ||| NNP
,  ||| S:843 E:845 ||| ,
T1-T2 ||| S:845 E:850 ||| NNP
,  ||| S:850 E:852 ||| ,
node-negative  ||| S:852 E:866 ||| JJ
disease ||| S:866 E:873 ||| NN
,  ||| S:873 E:875 ||| ,
who  ||| S:875 E:879 ||| WP
had  ||| S:879 E:883 ||| VBD
the  ||| S:883 E:887 ||| DT
required  ||| S:887 E:896 ||| JJ
treatment  ||| S:896 E:906 ||| NN
information  ||| S:906 E:918 ||| NN
available ||| S:918 E:927 ||| JJ
.  ||| S:927 E:929 ||| .
MRM  ||| S:929 E:933 ||| NNP
without  ||| S:933 E:941 ||| IN
RT  ||| S:941 E:944 ||| NNP
was  ||| S:944 E:948 ||| VBD
the  ||| S:948 E:952 ||| DT
most  ||| S:952 E:957 ||| RBS
common  ||| S:957 E:964 ||| JJ
treatment  ||| S:964 E:974 ||| NN
( ||| S:974 E:975 ||| -LRB-
43 ||| S:975 E:977 ||| CD
% ||| S:977 E:978 ||| NN
) ||| S:978 E:979 ||| -RRB-
.  ||| S:979 E:981 ||| .
Only  ||| S:981 E:986 ||| RB
17 ||| S:986 E:988 ||| CD
%  ||| S:988 E:990 ||| NN
underwent  ||| S:990 E:1000 ||| VBD
BCS ||| S:1000 E:1003 ||| NNP
.  ||| S:1003 E:1005 ||| .
Of  ||| S:1005 E:1008 ||| IN
the  ||| S:1008 E:1012 ||| DT
BCS  ||| S:1012 E:1016 ||| NNP
patients ||| S:1016 E:1024 ||| NNS
,  ||| S:1024 E:1026 ||| ,
46 ||| S:1026 E:1028 ||| CD
%  ||| S:1028 E:1030 ||| NN
received  ||| S:1030 E:1039 ||| VBD
adjuvant  ||| S:1039 E:1048 ||| JJ
RT  ||| S:1048 E:1051 ||| NN
to  ||| S:1051 E:1054 ||| TO
complete  ||| S:1054 E:1063 ||| VB
the  ||| S:1063 E:1067 ||| DT
traditional  ||| S:1067 E:1079 ||| JJ
BCT ||| S:1079 E:1082 ||| NNP
.  ||| S:1082 E:1084 ||| .
No  ||| S:1084 E:1087 ||| DT
deaths  ||| S:1087 E:1094 ||| NNS
were  ||| S:1094 E:1099 ||| VBD
recorded  ||| S:1099 E:1108 ||| VBN
in  ||| S:1108 E:1111 ||| IN
the  ||| S:1111 E:1115 ||| DT
BCT  ||| S:1115 E:1119 ||| NNP
group ||| S:1119 E:1124 ||| NN
,  ||| S:1124 E:1126 ||| ,
regardless  ||| S:1126 E:1137 ||| RB
of  ||| S:1137 E:1140 ||| IN
stage ||| S:1140 E:1145 ||| NN
,  ||| S:1145 E:1147 ||| ,
or  ||| S:1147 E:1150 ||| CC
in  ||| S:1150 E:1153 ||| IN
the  ||| S:1153 E:1157 ||| DT
3  ||| S:1157 E:1159 ||| CD
stage  ||| S:1159 E:1165 ||| NN
I  ||| S:1165 E:1167 ||| PRP
surgical  ||| S:1167 E:1176 ||| JJ
groups  ||| S:1176 E:1183 ||| NNS
if  ||| S:1183 E:1186 ||| IN
the  ||| S:1186 E:1190 ||| DT
men  ||| S:1190 E:1194 ||| NNS
had  ||| S:1194 E:1198 ||| VBD
received  ||| S:1198 E:1207 ||| VBN
RT ||| S:1207 E:1209 ||| NNP
.  ||| S:1209 E:1211 ||| .
The  ||| S:1211 E:1215 ||| DT
actuarial  ||| S:1215 E:1225 ||| JJ
5-year  ||| S:1225 E:1232 ||| NNP
CSS  ||| S:1232 E:1236 ||| NNP
was  ||| S:1236 E:1240 ||| VBD
100 ||| S:1240 E:1243 ||| CD
%  ||| S:1243 E:1245 ||| NN
in  ||| S:1245 E:1248 ||| IN
each  ||| S:1248 E:1253 ||| DT
BCT  ||| S:1253 E:1257 ||| NNP
group ||| S:1257 E:1262 ||| NN
.  ||| S:1262 E:1264 ||| .
MRM  ||| S:1264 E:1268 ||| NNP
alone  ||| S:1268 E:1274 ||| RB
resulted  ||| S:1274 E:1283 ||| VBN
in  ||| S:1283 E:1286 ||| IN
an  ||| S:1286 E:1289 ||| DT
actuarial  ||| S:1289 E:1299 ||| JJ
5-year  ||| S:1299 E:1306 ||| NNP
CSS  ||| S:1306 E:1310 ||| NNP
of  ||| S:1310 E:1313 ||| IN
97.3 ||| S:1313 E:1317 ||| CD
%  ||| S:1317 E:1319 ||| NN
for  ||| S:1319 E:1323 ||| IN
stage  ||| S:1323 E:1329 ||| NN
1 ||| S:1329 E:1330 ||| CD
%  ||| S:1330 E:1332 ||| NN
and  ||| S:1332 E:1336 ||| CC
91.2 ||| S:1336 E:1340 ||| CD
%  ||| S:1340 E:1342 ||| NN
for  ||| S:1342 E:1346 ||| IN
stageÂ 2 ||| S:1346 E:1353 ||| CD
.  ||| S:1353 E:1355 ||| .
The  ||| S:1355 E:1359 ||| DT
results  ||| S:1359 E:1367 ||| NNS
from  ||| S:1367 E:1372 ||| IN
our  ||| S:1372 E:1376 ||| PRP$
study  ||| S:1376 E:1382 ||| NN
suggest  ||| S:1382 E:1390 ||| VBP
that  ||| S:1390 E:1395 ||| IN
BCT  ||| S:1395 E:1399 ||| NNP
for  ||| S:1399 E:1403 ||| IN
early-stage  ||| S:1403 E:1415 ||| NNP
MBC  ||| S:1415 E:1419 ||| NNP
yields  ||| S:1419 E:1426 ||| NNS
comparable  ||| S:1426 E:1437 ||| JJ
survival  ||| S:1437 E:1446 ||| NN
compared  ||| S:1446 E:1455 ||| VBN
with  ||| S:1455 E:1460 ||| IN
more  ||| S:1460 E:1465 ||| RBR
invasive  ||| S:1465 E:1474 ||| JJ
treatment  ||| S:1474 E:1484 ||| NN
modalities  ||| S:1484 E:1495 ||| NNS
( ||| S:1495 E:1496 ||| -LRB-
ie ||| S:1496 E:1498 ||| UH
,  ||| S:1498 E:1500 ||| ,
MRM  ||| S:1500 E:1504 ||| NNP
or  ||| S:1504 E:1507 ||| CC
SM  ||| S:1507 E:1510 ||| NNP
alone ||| S:1510 E:1515 ||| RB
) ||| S:1515 E:1516 ||| -RRB-
.  ||| S:1516 E:1518 ||| .
This  ||| S:1518 E:1523 ||| DT
could  ||| S:1523 E:1529 ||| MD
shift  ||| S:1529 E:1535 ||| VB
the  ||| S:1535 E:1539 ||| DT
treatment  ||| S:1539 E:1549 ||| NN
paradigm  ||| S:1549 E:1558 ||| NN
to  ||| S:1558 E:1561 ||| TO
less-invasive  ||| S:1561 E:1575 ||| JJ
interventions  ||| S:1575 E:1589 ||| NNS
and  ||| S:1589 E:1593 ||| CC
might  ||| S:1593 E:1599 ||| MD
have  ||| S:1599 E:1604 ||| VB
the  ||| S:1604 E:1608 ||| DT
added  ||| S:1608 E:1614 ||| JJ
benefit  ||| S:1614 E:1622 ||| NN
of  ||| S:1622 E:1625 ||| IN
increased  ||| S:1625 E:1635 ||| JJ
functional  ||| S:1635 E:1646 ||| NN
and  ||| S:1646 E:1650 ||| CC
psychological  ||| S:1650 E:1664 ||| JJ
outcomes ||| S:1664 E:1672 ||| NNS
.  ||| S:1672 E:1674 ||| .
Further  ||| S:1674 E:1682 ||| RBR
prospective  ||| S:1682 E:1694 ||| JJ
studies  ||| S:1694 E:1702 ||| NNS
are  ||| S:1702 E:1706 ||| VBP
needed  ||| S:1706 E:1713 ||| VBN
to  ||| S:1713 E:1716 ||| TO
confirm  ||| S:1716 E:1724 ||| VB
our  ||| S:1724 E:1728 ||| PRP$
conclusions ||| S:1728 E:1739 ||| NNS
.  ||| S:1739 E:1741 ||| .
